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Abstract
Aims: Radiotherapy is an important treatment for many types of cancer, but a minority of patients suffer long-term side-effects of treatment. Multiple lines of
evidence suggest a role for circadian rhythm in the development of radiotherapy late side-effects.
Materials and methods:We carried out a study to examine the effect of radiotherapy timing in two breast cancer patient cohorts. The retrospective LeND cohort
comprised 535 patients scored for late effects using the Late Effects of Normal Tissue-Subjective Objective Management Analytical (LENT-SOMA) scale. Acute
effects were assessed prospectively in 343 patients from the REQUITE study using the CTCAE v4 scales. Genotyping was carried out for candidate circadian
rhythm variants.
Results: In the LeND cohort, patients who had radiotherapy in the morning had a signiﬁcantly increased incidence of late toxicity in univariate (P ¼ 0.03) and
multivariate analysis (P ¼ 0.01). Acute effects in the REQUITE group were also signiﬁcantly increased in univariate analysis after morning treatment (P ¼ 0.03)
but not on multivariate analysis. Increased late effects in the LeND group receiving morning radiotherapy were associated with carriage of the PER3 variable
number tandem repeat 4/4 genotype (P ¼ 6  103) and the NOCT rs131116075 AA genotype (P ¼ 5  103).
Conclusion: Our results suggest that it may be possible to reduce toxicity associated with breast cancer radiotherapy by identifying gene variants that affect
circadian rhythm and scheduling for appropriate morning or afternoon radiotherapy.
 2018 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Circadian rhythms are 24 h endogenous biological cy-
cles that inﬁltrate every aspect of physiology, biochem-
istry and behaviour in higher organisms. The phasing of
these rhythms can be adjusted by environmental factors
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creativecommons.org/licenses/by-nc-nd/4.0/).genotoxic agents. Circadian timing regulates rhythmic
events in the cell cycle, DNA repair, apoptosis and in the
immune system [1].
There is strong evidence that the response to xenobiotics,
including drugs, varies according to circadian rhythms, both
in terms of efﬁcacy and side-effects [2]. This has been
particularly demonstrated for some anti-cancer agents
[3e6].
Themain tissue at risk for acute and late effects of breast
radiotherapy is the skin and subcutaneous connective tis-
sue. Fibroblasts in the dermis and keratinocytes in the
epidermis show diurnal variation in cell proliferation ac-
tivity regulated by circadian rhythm genes [7]. The skin isd. This is an open access article under the CC BY-NC-ND license (http://
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sun. It has been postulated that the pattern of skin cellular
proliferation has adapted to this potentially harmful effect
during daylight hours and is under circadian control [8].
Although ultraviolet irradiation only penetrates as far as
the dermis it has similar effects on the epidermis as much
more penetrating X or gamma rays. Proliferating cells are
more radiosensitive or ultraviolet sensitive than non-
dividing cells (in G0) and radiosensitivity varies
throughout the cell cycle. Cells in the DNA synthetic phase
(S phase) are the least sensitive and cells just before
mitosis or during mitosis are the most sensitive (G2/M
phases) [9].
In humans, the maximum number of dividing epidermal
cells are in the radioresistant S phase at the time of maximal
potential solar exposure [8]. Janich and colleagues [7]
identiﬁed ﬁve peaks of circadian gene activity and prolif-
eration events in human keratinocytes in a 24 h cycle. Three
of the observed peaks were in the late evening and early
morning hours and were related to keratinocyte differen-
tiation. The other two peaks were in the afternoon and
evening hours and were related to DNA replication and cell
division. The family of Period genes (PER1e3) were
observed to be part of the auto-regulated feedback loop
involved in this process.
There has previously been mixed evidence for whether
radiotherapy side-effects are affected by the time of
treatment [10]. Noh et al. [11] examined the relationship
with radiotherapy treatment time and acute skin toxicity
in 395 breast cancer patients. They reported that patients
treated in the afternoon had more chance of developing
acute skin toxicity (Radiation Therapy Oncology Group
grade 2 or more) (P ¼ 0.0088). Bjarnason et al. [12] inves-
tigated the relationship of treatment time to grade 3 or
more mucositis in head and neck patients treated with
radical doses of radiotherapy but failed to show a signiﬁ-
cant difference between morning and afternoon groups.
However, on subgroup analysis, when patients were
divided by gender there was a trend that women had
enhanced toxicity in the morning, whereas men showed
the effect in the afternoon. A gender-speciﬁc circadian
rhythm response has also been seen for chemotherapy
response [13,14].
A variable number tandem repeat (VNTR) polymorphism
in the PER3 gene has been found to be associated with
sleepewake patterns, with the 5 allele associated with
morningness [15]. Earlier evidence found that the C allele of
rs1801260 SNP in the CLOCK gene was associated with
eveningness [16].
A genome-wide association study for breast cancer side-
effects found an association between adverse reactions and
a single nucleotide polymorphism (SNP) in a circadian
rhythm gene called Nocturnin (NOCT), which encodes a
RNA deadenylase [17]. The SNP was the top hit associated
with overall radiosensitivity with a P value of 1.21  106,
which, however, does not meet the conventional signiﬁ-
cance cut-off for a genome-wide association study. These
data led us to investigate potential circadian effects on
radiotherapy treatment.Materials and Methods
Patient Selection and Assessment
All patients were recruited after gaining appropriate
consent and ethics approval was granted by the National
Health Service research and ethics committee and health
research authority.
LeND Cohort
For the assessment of late radiotherapy effects, a group of
664 breast cancer patients previously recruited to the LeND
study were assessed as previously described [18e20]. Most
patients received 50 Gy of radiation in 25 fractions. Partic-
ipants were recruited at follow-up oncology clinics from
2008 to 2010 in Leicester, Nottingham and Derby at least 3
years after adjuvant radiotherapy treatment (median
follow-up time 62 months). Radiotherapy toxicity was
recorded using the Late Effects of Normal Tissue-Subjective
Objective Management Analytical (LENT-SOMA) criteria
[21]. At the same visit, volunteers donated a blood sample
or buccal cheek swab for DNA extraction. Samples of frozen
isolated DNA (1 ng/ml) obtained from whole blood were
available for volunteers 150e633.
REQUITE Cohort
In total, 343 breast cancer patients were recruited at
Leicester Royal Inﬁrmary to the international European
Union-funded REQUITE study [22] between 2014 and
2016. All breast cancer patients underwent a wide local
excision before adjuvant whole breast radiotherapy. Most
patients received 40 Gy of radiation in 15 fractions. Co-
morbidity data were recorded by the clinical team, with
depression being deﬁned as having a clinical diagnosis of
depression.
Patients were assessed by a clinician at baseline and
again within the last three fractions of radiotherapy to re-
view any acute reactions using an adapted version of the
CTCAE v4 scoring system. At the same time as the baseline
assessment, a 10 ml sample of fresh whole blood was
collected in an EDTA tube. This was transferred to the
CIGMR Biobank (Manchester, UK) who isolated DNA using
robotic magnetic bead extraction technology. The isolated
DNA (20 ng/ml) was then stored at e80 C.
Radiotherapy Timing
Scheduling of radiotherapy treatment in most cases is a
result of department capacity and patient request. At the
Leicester Royal Inﬁrmary, radiotherapy records were
reviewed to obtain the time of treatment for every fraction
received. Patients with more than 66% of their radiotherapy
before noon were classiﬁed as morning treatment; patients
who received more than 66% after noon were classiﬁed as
afternoon treatment; those falling outside these criteria
were classiﬁed as a mixed group.
K. Johnson et al. / Clinical Oncology 31 (2019) 9e16 11Radiotherapy had been delivered in Leicester, UK, which
is at latitude 52.6N and has daylight savings time. For the
purposes of this analysis, seasons were grouped around the
solstices, with the darkest half of the year being 20
September to 20 March and the lightest half of the year
being 21 March to 19 September.
DNA Analysis
Of the 664 LeND patients, DNA was available for geno-
typing on 508 patients. In the REQUITE cohort, DNA was
available for genotyping in 324 of 343 patients.
PER3
In both cohorts, the PER3 VNTR region was ampliﬁed by
polymerase chain reaction (PCR) and agarose gel electro-
phoresis was carried out. The two alleles are differentiated
by an extra 56 bp repeat in the 5 allele: 4/4 VNTR showed a
single band at 639 bp, 4/5 genotype showed two bands at
639 and 685 bp 5/5 VNTR showed a single band at 685 bp.
In the LeND cohort, PCR for PER3 VNTR was successful in
476 patients; in the remaining 32 samples there was inad-
equate DNA to produce reliable results. In total, 225 patients
were 4/4, 191 patients were 4/5 and the remaining 60 pa-
tients 5/5 genotype.
In the REQUITE cohort, PCR was successful in 309 pa-
tients. In total, 140 patients were found to have 4/4, 136 4/5
and the remaining 33 patients were 5/5 genotype. Geno-
typing results were tested and found to be in
HardyeWeinberg equilibrium.
NOCT rs13116075
NOCT rs13116075 was genotyped by Taqman assay.
Supplementary Figure S1 shows the plots that resulted from
this assay.
In the LeND cohort, PCR for NOCT rs13116075 was suc-
cessful in 466 patients; in the remaining 42 samples there
was inadequate DNA to produce reliable results. In total, 317
patients were AA, 141 were AG and the remaining eight
were GG genotypes. In the REQUITE cohort, genotyping was
successful in 323 patients; the remaining one patient
sample failed to produce reliable results. Genotyping
revealed that 233 patients were AA, 80 were AG and 10
were GG. Genotype frequencies were found to be in
HardyeWeinberg equilibrium.
CLOCK rs1801260
CLOCK rs1801260 was genotyped by Taqman assay in
just the REQUITE cohort. Supplementary Figure S2 shows
the plots that resulted from this assay.
Statistical Analysis
For acute toxicity (in REQUITE) breast erythema was
taken as a surrogate marker of overall acute toxicity. Anybaseline score was deducted from the score assessed within
the last three fractions of radiotherapy to give a corrected
acute toxicity score.
Late toxicity (in LeND) was assessed using Bivariate STAT
score. Use of the STAT score was described by Barnett et al.
[17] and has been used previously as a dichotomised vari-
able [18]. In brief, a Z score was calculated for each patient
and all toxicity end points (i.e. ﬁbrosis, telangiectasia, at-
rophy, oedema) (Z ¼ [score e mean score]/standard devia-
tion for the whole population). A STAT score can then be
calculated as an average of the patient Z scores. The popu-
lation are then divided into upper quartile and lower three-
quarters to form a bivariate STAT score.
Statistical analysis was carried out using IBM SPSS
version 24. Differences in categorical variables were ana-
lysed by chi-squared test. Multivariable analysis was carried
out using logistic regression. Covariates were selected by
bidirectional elimination.Results
Radiotherapy Treatment Time
The LeND Cohort
In total, 664 women were enrolled in the LeND cohort
and of these radiotherapy treatment time was available
for 536 patients. Of those with no data, 75 were
recruited in subsites and 53 received radiotherapy before
computerised records became available in 1998. Patients
were grouped according to treatment time: 185 patients
(34.5%) received radiotherapy mainly in the morning, 170
patients (31.7%) received radiotherapy mainly in the af-
ternoon and 181 (33.8%) had a mix of treatment times.
Patients received either 45 Gy X-rays in 20 fractions or
50 Gy in 25 fractions. Seventy-six patients received a
9e15 Gy electron boost in three to ﬁve fractions. Base-
line characteristics for these patients by group are shown
in Table 1. Chi-squared testing for categorical variables
and ANOVA testing for continuous variables revealed
that none of these baseline characteristics was signiﬁ-
cantly different between the treatment time groups. The
only exception was if the mixed group were excluded
from the analysis, then signiﬁcantly more patients
received a boost in the morning compared with the af-
ternoon (P ¼ 0.04).
Late toxicity (bivariate STAT score) was available on 536
of the patients. Univariate analysis using a chi-squared test
was carried out and showed a signiﬁcantly increased fre-
quency of toxicity in patients treated in themornings: 29.2%
of the morning treatment group had high toxicity compared
with 21.1% of the afternoon group and 17.7% of the mixed
group (P ¼ 0.03). Multivariable analysis was carried out
using logistic regression and radiotherapy treatment time
remained signiﬁcant (P ¼ 0.01). Results are summarised in
Table 2. An interaction term for boost  treatment time was
included due to the difference between the groups in the
proportion receiving boosts.
Table 1
Baseline tumour, patient and treatment characteristics for the LeND cohort. Percentages are of non-missing data within each time group
Patients Radiotherapy treatment time P ¼
AM Mixed PM Total
185 181 170 536
Age (mean years) 59.1 57.4 58.7 0.28
Grade 1 29 (16.9%) 40 (25.8%) 39 (24.8%) 108 (22.3%)
2 81 (47.1%) 73 (47.1%) 67 (42.7%) 221 (45.7%) 0.20
3 62 (36.0%) 41 (26.5%) 51 (32.5%) 154 (31.8%)
Missing 13 26 13 52
Chemotherapy Yes 71 (38.4%) 49 (27.1%) 49 (29.0%) 169 (31.6%)
No 114 (61.6%) 132 (72.9%) 120 (71.0%) 366 (68.4%) 0.05
Missing 0 0 1 1
Oestrogen receptor positive Yes 162 (88.5%) 147 (82.1%) 141 (82.9%) 450 (84.6%)
No 21 (11.5%) 32 (17.9%) 29 (17.1%) 82 (15.4%) 0.19
Missing 2 1 0 3
Mean radiotherapy dose (Gy) 47.8 47.8 48 0.76
Boost to tumour bed Yes 36 (19.6%) 22 (12.2%) 20 (11.8%) 78 (14.6%)
No 148 (80.4%) 159 (87.8%) 150 (88.2%) 457 (85.4%) 0.06
Missing 1 0 0 1
Diabetes Yes 15 (8.1%) 6 (3.3%) 12 (7.1%) 33 (6.2%)
No 170 (91.9%) 175 (96.7%) 158 (92.9%) 503 (93.8%) 0.14
Smoker Current smoker 27 (14.9%) 21 (11.7%) 16 (9.5%) 64 (12.1%)
No 134 (74.0%) 138 (76.7%) 121 (72.0%) 393 (74.3%) 0.16
Ex-smoker 20 (11.0%) 21 (11.7%) 31 (18.5%) 72 (13.6%)
Missing 4 0 2 6
Side of treatment Right 100 (54.1%) 102 (56.4%) 90 (52.9%) 292 (54.5%)
Left 79 (42.7%) 73 (40.3%) 78 (45.9%) 230 (42.9%) 0.59
Bilateral 6 (3.2%) 6 (3.3%) 2 (1.2%) 14 (2.6%)
Bra cup size AeAA 13 (9.2%) 9 (6.8%) 16 (11.9%) 38 (9.3%)
B 53 (37.3%) 40 (30.0%) 41 (30.4%) 134 (33.7%)
C 34 (23.9%) 36 (27.1%) 27 (20.0%) 96 (23.6%) 0.38
D 22 (15.5%) 16 (12.1%) 22 (16.3%) 60 (14.6%)
DDeGG 20 (14.0%) 32 (24.1%) 29 (21.4%) 71 (19.7%)
Missing 43 48 35 126
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Data
Radiotherapy treatment time was available for 343 of the
REQUITE Leicester breast cohort. In total, 111 patients (32.4%)
received radiotherapy in themorning,152were treated in the
afternoon (44.3%) and 80 (23.3%) received a mix of morning
and afternoon treatment. Table 3 summarises the baseline
characteristics of the tumour, patient and treatment between
the treatment times. Chi-squared testing for categorical vari-
ables and ANOVA testing for continuous variables revealed
that signiﬁcantly more patients in the morning groupTable 2
Multivariate analysis (LeND cohort) for effect on late toxicity (bivariate
Variable P Value
Boost to tumour bed 0.58
BED 0.03
Cup size 5.1  107
Afternoon radiotherapy treatment 0.01
Boost  time 1.0  103
BED, biological equivalent dose.received a boost (P ¼ 0.01) and had higher grade tumours
(P ¼ 0.01) compared with the afternoon and mixed groups.
Acute breast erythema score was available on 331 of the
study participants. Univariate analysis using a chi-squared
test was carried out and showed a signiﬁcantly increased
toxicity rate in patients treated in the mornings: 23.6% of
patients had grade 2 or more erythema in the morning
group compared with 11.0% in the afternoon group and
19.0% in the mixed group (P ¼ 0.03). Removal of the mixed
treatment time group from the analysis resulted in a P value
of 7.0  103. Multivariable analysis was carried out usingSTAT score)
Odds ratio 95% conﬁdence interval for
odds ratio
Lower Upper
2.32 0.12 45.52
70.54 1.64 3044
1.27 1.16 1.39
0.61 0.41 0.90
6.80 2.23 20.63
Table 3
Baseline characteristics in the REQUITE cohort for tumour, patient and treatment. Percentages are of non-missing data within each time
group
Patients Radiotherapy treatment time P ¼
AM Mixed PM Total
111 80 152 343
Age (mean years) 60.0 61.4 60.5 0.60
Grade 1 25 (28%) 9 (14%) 35 (30%) 69 (25%)
2 36 (40%) 38 (58%) 65 (55%) 139 (51%)
3 28 (31%) 18 (28%) 18 (15%) 64 (24%) 0.008
Missing 22 15 34 71
Chemotherapy Yes 4 (4%) 6 (9%) 11 (9%) 21 (7%)
No 87 (96%) 62 (91%) 111 (91%) 260 (93%) 0.40
Missing 20 12 30 62
Oestrogen receptor positive Yes 50 (55%) 35 (51%) 68 (55%) 150 (54%)
No 41 (45%) 33 (49%) 56 (45%) 130 (46%) 0.89
Missing 20 12 31 63
Mean radiotherapy dose (Gy) 41.2 40.8 41.0 0.77
Boost to tumour bed Yes 12 (13%) 5 (7%) 3 (2%) 20 (8%)
No 79 (87%) 63 (93%) 119 (98%) 261 (93%) 0.01
Missing 20 12 30 62
Diabetes Yes 8 (7%) 7 (9%) 14 (9%) 29 (8%)
No 103 (93%) 72 (91%) 138 (91%) 313 (92%) 0.84
Missing 0 1 0 1
Smoker Current smoker 14 (14%) 4 (7%) 19 (17%) 37 (14%)
No 39 (40%) 27 (44%) 45 (39%) 111 (41%)
Ex-smoker 44 (45%) 30 (49%) 50 (44%) 124 (46%) 0.47
Missing 14 19 38 71
Side of treatment Right 48 (54%) 36 (54%) 61 (50%) 145 (52%)
Left 41 (46%) 31 (46%) 61 (50%) 133 (48%) 0.82
Bilateral 0 0 0 0
Missing 22 13 30 65
Body mass index 29.1 27.9 29.7 0.59
Bra cup size AAeA 9 (8.1%) 6 (7.6%) 8 (5.3%) 23 (6.7%)
B 33 (29.7%) 19 (24.1%) 43 (28.5%) 95 (27.9%)
C 24 (21.6%) 13 (16.5%) 41 (27.2%) 78 (22.9%)
D 18 (16.2%) 15 (19.0%) 27 (17.9%) 60 (17.6%)
DDeJ 27 (24.3%) 26 (32.9%) 32 (21.2%) 85 (24.9%) 0.35
Missing 1 1 2
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signiﬁcant (P ¼ 0.28). Results are summarised in Table 4.Genetic Variants as Effect Modiﬁer
We tested if the time-of-day effect is modiﬁed by
candidate polymorphisms in circadian rhythm genes,
including SNPs in the CLOCK and NOCT genes and a VNTR in
the PER3 gene.
LeND Cohort
There was no signiﬁcant direct relationship between
PER3 VNTR and late toxicity (bivariate STAT score). Taking
the time of radiotherapy into consideration showed a sig-
niﬁcant effect of PER3 VNTR on late toxicity, with 4/4 PER3
VNTR being associated with increased toxicity if treated in
the morning compared with the afternoon (P ¼ 6.0  103)(Table 5). A Bonferroni correction for six tests (based on six
genotypes in Table 5) would give a P value of 0.036.
There was no signiﬁcant direct relationship with NOC
rs13116075 and late toxicity (bivariate STAT score). Taking
the time of radiotherapy treatment into consideration
showed a signiﬁcant effect of NOC rs13116075 on late
toxicity. Patients carrying the AA NOC rs13116075 genotype
had increased toxicity if treated in the mornings
(P ¼ 5.0  103) (Table 5). A Bonferroni correction for six
tests would give a P value of 0.03.
Combination of PER3 VNTR and NOCT rs13116075 ge-
notypes had no signiﬁcant direct effect on late radiotherapy
toxicity. However, taking the time of radiotherapy treat-
ment into consideration showed a signiﬁcant effect of NOCT
rs13116075 and PER3 VNTR on late toxicity. Patients with
AA NOCT rs13116075 genotype and 4/4 PER3 VNTR had
increased late radiotherapy toxicity if treated in the morn-
ings (P ¼ 4.5  104) (data not shown).
Table 5
Late toxicity split by PER, NOCT rs13116075 and radiotherapy treatment time in the LeND cohort
Radiotherapy
treatment time
PER3 VNTR Late toxicity (bivariate
STAT score) n ¼
P Value* NOCT rs13116075 Late toxicity (bivariate
STAT score n ¼)
P Value*
75% lowest 25% highest 75% lowest 25% highest
Morning 4/4 43 (68.3%) 20 (31.7%) 6.0  103 AA 61 (76.7%) 29 (23.3%) 5.0  103
Afternoon 49 (79.0%) 13 (21.0%) 80 (85.1%) 14 (14.9%)
Mixed 54 (91.5%) 5 (8.5%) 72 (84.7%) 13 (15.3%)
Morning 4/5 37 (77.1%) 11 (22.9%) 0.49 AG 22 (75.9%) 7 (24.1%) 0.74
Afternoon 51 (85.0%) 9 (15.0%) 34 (75.6%) 11 (24.4%)
Mixed 45 (77.6%) 13 (22.4%) 36 (81.8%) 8 (18.2%)
Morning 5/5 11 (73.3%) 4 (26.7%) 0.75 GG 3 (100%) 0 0.08
Afternoon 12 (66.7%) 6 (33.3%) 1 (33.3%) 2 (66.7%)
Mixed 14 (77.8%) 4 (22.2%) 0 0
Total 316 85 316 85
VNTR, variable number tandem repeat.
* Chi-squared test for signiﬁcance including all treatment times.
Table 4
Multivariate analysis of the REQUITE breast cohort for the effect on acute toxicity
Variable P Value Odds ratio 95% conﬁdence interval for
odds ratio
Lower Upper
Bra cup size 4.90  105 1.71 1.32 2.23
Depression 0.02 0.07 0.01 0.62
Boost to tumour bed 0.64 1.66 0.20 14.17
Boost  radiotherapy time 0.49 1.89 0.31 11.64
Season 0.65 1.21 0.53 2.72
Afternoon radiotherapy treatment 0.28 0.76 0.46 1.25
Biological equivalent dose 1.57  107 1.45 1.26 1.66
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There was no association between PER3 VNTR genotype
and acute toxicity score in the 294 patients with data
available for both (P¼ 0.79). Taking the time of radiotherapy
treatment into consideration showed no signiﬁcant effect of
PER3 VNTR on acute toxicity with any of the genotypes
(Table 6). If the mixed treatment time group was excluded
from the analysis, patients with 4/5 PER3 VNTR had
increased acute toxicity with morning compared with af-
ternoon treatment (P ¼ 0.02).
Acute toxicity score was available for 308 of the 323
breast patients, with genotyping data available for NOC
rs13116075. The NOC rs13116075 AG genotype was signiﬁ-
cantly associated with increased toxicity (P ¼ 0.04), but not
after applying a correction for multiple testing. The other
genotypes were not related to toxicity.
Taking the time of radiotherapy treatment into consid-
eration showed no signiﬁcant effect of NOC rs13116075
(Table 6) on acute toxicity with any of the genotypes. If the
mixed treatment time group was excluded from the anal-
ysis, patients with AG NOC rs13116075 had increased acute
toxicity in the mornings (P ¼ 0.04). A Bonferroni correction
for eight tests would render these results non-signiﬁcant.
Combination of PER3 VNTR and NOCT rs13116075 had no
direct associationwith increased late toxicity. Nor was thereany evidence of the combination modifying the time-of-day
effect on toxicity score. There was no effect of CLOCK ge-
notype in any analysis.Discussion
In this study we found some evidence that breast cancer
patients treated in the morning had worse radiotherapy
side-effects than those treated in the afternoon.
These results are in contrast with some earlier studies
[10,11], but the differences are probably due to differences
in the gender of patients, irradiated tissue type, geograph-
ical latitude, allocation of time groups and methods of
booking patients into radiotherapy.
To enable the reduction of side-effects while maintaining
activity in radiotherapy suites over the whole day it is
necessary to be able to predict which patients would beneﬁt
from having their treatment delivered at a deﬁned time of
day (chronotherapy). To that end we carried out genotyping
for some candidate circadian rhythm polymorphisms and
found that the circadian effect was strongest in individuals
who were homozygous for the PER3 4 repeat or NOCT A
alleles. Importantly, these alleles were not found to be
directly associated with radiotherapy toxicity in this study,
Table 6
Acute breast erythema split by PER3 and NOCT rs13116075 genotyping and radiotherapy treatment time in the REQUITE breast cohort
Treatment time PER3 VNTR Acute toxicity (breast
erythema score) n ¼
P Value NOCT rs13116075 Acute toxicity (breast
erythema score) n ¼
P Value
<2 2 <2 2
Morning 4/4 31 (81.6%) 7 (18.4%) 0.71*/0.71y AA 59 (80.8%) 14 (19.2%) 0.21*/0.18y
Afternoon 49 (84.5%) 9 (15.5%) 83 (88.3%) 11 (11.7%)
Mixed 31 (88.6%) 4 (11.4%) 49 (90.7%) 5 (9.3%)
Morning 4/5 32 (72.7%) 12 (27.3%) 0.07*/0.02y AG 15 (65.2%) 8 (34.8%) 0.06*/0.04y
Afternoon 53 (89.8%) 6 (10.2%) 30 (88.2%) 4 (11.8%)
Mixed 20 (76.9%) 6 (23.1%) 10 (62.5%) 6 (37.5%)
Morning 5/5 9 (81.8%) 2 (18.2%) 0.19*/0.16y GG 1 (100%) 0 N/A
Afternoon 10 (100%) 0 5 (100%) 0
Mixed 7 (70.0%) 3 (30.0%) 1 (100%) 0
TOTAL 242 49 253 51
VNTR, variable number tandem repeat.
* Chi-squared test for signiﬁcance including all treatment times.
y Chi-squared test for signiﬁcance excluding the mixed treatment times group.
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that larger studies would ﬁnd a direct association, as the
NOCT SNP was previously found to be associated with
overall toxicity by genome-wide association study. The PER
group of genes are intimately connected with the control
and timing of keratinocyte division [7]. Nocturnin has been
shown to affect the proliferation of adipocytes, an impor-
tant cell type in the breast [23].
There are several potential physiological mechanisms to
explain how time could affect reactions to irradiation, e.g.
melatonin, cortisol, inﬂammatory factors or cell prolifera-
tion/DNA damage. Melatonin has antioxidant properties
[24], has been shown to be radioprotective in mice [25] and
reduce oral mucositis in irradiated rats [26]. Cortisol levels
can be used as a marker of stress and can affect inﬂamma-
tory markers [27]. Cortisol levels can inﬂuence the rate of
cell division and may be associated with possible increased
cellular division of skin in the morning compared with later
in the day [28].
Many clinical studies have shown a weak association
between acute and late toxicity, with some making a
distinction between consequential and non-consequential
late effects [29]. Therefore, the fact that the time-of-day
effect is the same in the present study for acute and late
toxicity may give a clue to the mechanism. Future work will
determine how the cell cycle of keratinocytes and ﬁbro-
blasts responds to circadian rhythms.
There were several limitations of this study. First, the
study was conducted at a single centre and therefore the
generalisability of the results will not be known until
replicated at other centres. Second, acute and late toxicity
were assessed in different cohorts who received radio-
therapy in different calendar years with different radio-
therapy protocols, which complicates interpretation and
adjustment for multiple testing. Added to this is that the
LeND cohort was collected retrospectively, meaning no
assessment was possible of tissue changes from baseline.
This will be remedied when late toxicity data become
available for the REQUITE cohort. Acute toxicity in the
REQUITE cohort was recorded before the end ofradiotherapy, so will have missed manifestations occurring
some weeks later. Third, the cohort sizes limit the statistical
power to detect effects; larger cohorts are needed to
conﬁrm the data.
These genetic data potentially open the possibility of a
simple test to identify the patients who would beneﬁt from
receiving their treatment in the afternoon, whereas the
remaining patients could be treated at any time. This
approach will need to be veriﬁed using a clinical trial that
randomises between a group in which patients choose their
own treatment time and a chronotherapy group. This virtu-
ally cost-free interventionwould be predicted to reduce side-
effects and improve quality of life for breast cancer survivors.Conﬂicts of interest
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